title: Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial.
abstract: To examine the outcome of patients with persistent coronary artery occlusion despite treatment with intravenous tissue-type plasminogen activator (t-PA), the clinical course of 96 patients with persistent occlusion after 90 min of therapy was evaluated. All patients underwent cardiac catheterization 90 min after initiation of intravenous t-PA. Immediate coronary angioplasty (PTCA) was attempted when the infarct-related artery failed to reperfuse unless the vessel was technically unsuitable or the infarct was thought to be small. No baseline differences could be found between these 96 patients and 288 patients who achieved perfusion with the same protocol. Although patients with and without successful perfusion after t-PA had similar clinical courses before cardiac catheterization, those without perfusion had more complications (ventricular fibrillation, severe bradycardia, hypotension) during catheterization. PTCA achieved reperfusion with less than 50% residual stenosis in 73% of the 86 patients in whom it was attempted, while 16% were left with a high-grade (greater than 50%) residual stenosis and PTCA failed in 11%. Mortality was highest in the nine patients with complete PTCA failure (44%), compared with a 6% mortality in the 63 patients with an insignificant residual stenosis after PTCA and a 14% mortality in the 14 patients with reperfusion, but a greater than 50% residual stenosis after PTCA. In 10 patients with small infarcts (six), unsuitable anatomy (two), or "spontaneous" drug induced (but later) opening before contemplated PTCA (two), PTCA was not attempted and no mortality occurred. The in-hospital reocclusion rate after successful PTCA was 29%, despite the use of heparin and antiplatelet agents.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710.
authors.forename: R M
authors.initials: RM
authors.lastname: Califf
authors.forename: E J
authors.initials: EJ
authors.lastname: Topol
authors.forename: B S
authors.initials: BS
authors.lastname: George
authors.forename: J M
authors.initials: JM
authors.lastname: Boswick
authors.forename: K L
authors.initials: KL
authors.lastname: Lee
authors.forename: D
authors.initials: D
authors.lastname: Stump
authors.forename: J
authors.initials: J
authors.lastname: Dillon
authors.forename: C
authors.initials: C
authors.lastname: Abbottsmith
authors.forename: R J
authors.initials: RJ
authors.lastname: Candela
authors.forename: D J
authors.initials: DJ
authors.lastname: Kereiakes
mesh_terms: D000800:Angioplasty, Balloon; D006328:Cardiac Catheterization; D002986:Clinical Trials as Topic; D017023:Coronary Angiography; D003327:Coronary Disease / Q000628:therapy*; D003328:Coronary Thrombosis / Q000401:mortality / Q000628:therapy*; D004359:Drug Therapy, Combination; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D011897:Random Allocation; D011994:Recombinant Proteins / Q000008:administration & dosage; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D014654:Vascular Patency / Q000187:drug effects
chemical_list: D011994:Recombinant Proteins; D006493:Heparin; D010959:Tissue Plasminogen Activator